Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?

Table 1

Results of colorectal cancer and adenoma incidence in aspirin trials.

Study	Year	Cohort	N° cases	Intervention	End Point	RR
PHS (Gann)	1993	Healthy	22071	325 mg every other day versus placebo	CCR incidence	1.15; 0.80–1.65
PHS (Stürmer)	1998	Healthy	22071	325 mg every other day versus placebo	CCR incidence	1.03; 0.83–1.28
Cook et al.	2004	Healthy	39876	100 mg every other day	CCR incidence	0.97; 0.77–1.24
Baron et al.	2003	Prior adenoma	1121	81 mg versus 325 mg daily versus placebo	Adenomas incidence	0.81*; 0.69–0.96
Sandler et al.	2003	Prior CCR	635	325 mg daily versus placebo	Adenomas incidence	0.65; 0.46–0.91
APPAC	2003	Prior adenoma	272	160 mg versus 325 mg versus placebo**	Adenomas incidence	0.73; 0.52–1.04

*Positive for 81 mg arm. **Negative for both arms.